37
3
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T15238 |
Epoprostenol sodium
Prostaglandin I2 sodium salt,Prostacyclin sodium salt,Flolan |
Others | Others |
Epoprostenol sodium is a potent inhibitor of platelet aggregation used in pulmonary hypertension and transplantation. | |||
T26745 |
BAY 73-1449
BAY-73-1449,BAY73-1449 |
Others | Others |
BAY 73-1449 是前列环素受体选择性拮抗剂,在人 HEL 细胞和大鼠 DRG 的 cAMP 分析中具有很高的效价,IC50小于 0.1 nM。BAY 73-1449在降血压方面有研究的价值。 | |||
T36236 |
5-cis Carbaprostacyclin
|
||
5-cis Carbaprostacyclin is a stable analog of PGI2 and an isomer of carbaprostacyclin. It is a weak inhibitor of human platelet aggregation with an IC50 of 2.8 μM compared to 0.3 μM for carbaprostacyclin. 5-cis Carbaprostacyclin is a much weaker effector of rabbit mesenteric artery relaxation with an EC50 of 104 μM compared to 5.9 μM for carbaprostacyclin. It even antagonizes the adenylate cyclase activation induced by carbaprostacyclin. | |||
T36774 |
13,14-dehydro-15-cyclohexyl Carbaprostacyclin
|
||
13,14-dehydro-15-cyclohexyl Carbaprostacyclin is a chemically stable analog of PGI2. It inhibits the ADP-induced aggregation of human platelets with an ED50 of about 40 nM in PRP and 77 nM in washed platelets, which is comparable to the potency of carbaprostacyclin. | |||
T3216 |
Selexipag
NS-304,ACT-293987,赛乐西帕,Uptravi |
Others; Prostaglandin Receptor | GPCR/G Protein; Immunology/Inflammation; Others |
Selexipag (ACT-293987) 是前列环素受体激动剂,可引起肺血管舒张,用于治疗肺动脉高压。 | |||
T69360 |
RO3244794
|
Prostaglandin Receptor | GPCR/G Protein; Immunology/Inflammation |
RO3244794是一种具有选择性的前列环素 (IP)受体拮抗剂,可用于研究肝脏损伤。 | |||
T4635 |
Ralinepag
APD811 |
Others; Prostaglandin Receptor | GPCR/G Protein; Immunology/Inflammation; Others |
Ralinepag (APD811) 是一种可口服的非前列腺素前列环素 (IP) 受体激动剂,对人和大鼠 IP 受体以及人 DP1 受体的 EC50 分别为 8.5、530 和 850 nM。 | |||
TP1277 |
Bradykinin
缓激肽 |
Endogenous Metabolite; Bradykinin Receptor | GPCR/G Protein; Metabolism |
Bradykinin 是由激肽释放酶-激肽系统产生的活性肽。 它是炎症调节因子和神经调节因子,对几种血管和肾功能也有调节作用。 | |||
T21443 |
Prednicarbate
Hoe 777,Hoe-777,Dermatop E emollient,UNII-V901LV1K7D |
Others | Others |
Prednicarbate (Hoe 777) 是一种外用皮质类固醇。Prednicarbate 可用于炎症性皮肤病的研究,如特应性皮炎。 | |||
T4436 |
RO1138452
CAY10441 |
Others; Prostaglandin Receptor | GPCR/G Protein; Immunology/Inflammation; Others |
RO1138452 (CAY10441) 是一种选择性和可口服的前列环素受体拮抗剂,pKi 为8.3。它拮抗卡前列环素诱导的人神经母细胞瘤腺苷酸环化酶的激活,以剂量依赖性方式阻断环 AMP 积累,具有镇痛活性。 | |||
T34417 |
RS 93427-007
RS-93427-007,RS93427-007 |
||
RS-93427-007 is an orally active stable mimetic agent of prostacyclin for the study of mechanisms of atherogenesis. | |||
T68751 | Hoe 892 | ||
Hoe 892 is a stable thia-thimo-analogue of prostacyclin and acts as a platelet aggregation inhibitor. | |||
T34796 |
TEI-9063
TEI9063 |
||
TEI-9063 is a stable and highly specific prostacyclin analogue of prostacyclin receptor in mast cell tumor p-815 cells. | |||
T30426 |
Beraprost
ML 1229,MDL 201229,ML-1229,MDL-201229 |
||
Beraprost is a stable prostacyclin analog. | |||
T33579 |
Nafazatrom
Nafazatromum |
||
Nafazatrom is a pyrazolinone derivative and lipoxygenase inhibitor that increases endogenous prostacyclin (PGI2) and has experimental anticancer activity. Nafazatrom is also an antithrombotic drug that increases prostacyclin levels and reduces the inciden | |||
T23657 |
AFP-07
AFP07 |
||
AFP-07 is a highly selective and potent agonist. It was used for the prostacyclin receptor. | |||
T71025 |
KP 10614
|
||
KP 10614 is a new prostacyclin analog that inhibits platelet-polymorphonuclear leukocyte interaction. | |||
T28254 |
OP-2507
|
||
OP-2507, a prostacyclin agonist, is used potentially for the treatment of hepatic insufficiency and hypertension. | |||
T10673 |
Carbacyclin
Carbaprostacyclin,Carba-PGI2 |
Others | Others |
Carbacyclin, a PGI2 analog, is a prostacyclin (PGI2) receptor agonist and vasodilator with potent inhibitory platelet aggregation. | |||
T38171 | Ro 1138452 hydrochloride | ||
Selective prostacyclin IP receptor antagonist (pKi = 8.3). Exhibits no affinity at other prostanoid receptors (EP1-4, FP and TP) in a radioligand binding assay. Demonstrates analgesic activity in rats. Orally bioavailable. Clark et al (2004) Discovery and SAR development of 2-(phenylamino) imidazolines as prostacyclin receptor antagonists. Bioorg.Med.Chem.Lett. 14 1053 PMID:15013022 |Jones et al (2006) Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel ... | |||
T15560 |
Iloprost
ZK 36374,Ciloprost,伊洛前列素 |
Others | Others |
Iloprost is a synthetic analogue of prostacyclin PGI2. Iloprost commonly employed in the treatment of peripheral vascular disease and also indicated in the treatment of patients affected by systemic sclerosis (SSc) in the presence of severe Raynaud's phen | |||
T61526 | Cicaprost | ||
Cicaprost (ZK 96480) is a prostacyclin receptor (IP) agonist, which induces relaxation of the artery via concentration-dependent mechanisms. Its EC50 value, determined to be 5.8 nM [1], further highlights its potency. | |||
T36211 |
16(R)-Iloprost
|
||
Iloprost is a second generation structural analog of prostacyclin (PGI2) with about ten-fold greater potency than the first generation stable analogs, typified by carbaprostacyclin. Iloprost binds with equal affinity to the recombinant human IP and EP1 receptors with a Ki value of 11 nM. Most preparations of iloprost contain 16(S) and 16(R) stereoisomers. 16(R)-Iloprost inhibits platelet aggregation with an IC50 value of 65 nM. | |||
T68639 |
Ciprostene (free base)
|
||
Ciprostene (free base) is a synthetic, chemically stable analog of prostacyclin (PGI2). In animal models, administration of ciprostene resulted in dose-dependent hypotension, tachycardia, and inhibition of ex vivo ADP-induced platelet aggregation. Ciprostene was evaluated in clinical trials in patients with peripheral vascular disease. It was found to reduce restenosis in patients with coronary artery disease undergoing therapeutic percutaneous transluminal coronary angioplasty. | |||
TMIH-0520 |
Selexipag-d7
|
||
Selexipag-d7 是 Selexipag 的氘代化合物。Selexipag 的 CAS 号为 475086-01-2。Selexipag 是前列环素受体激动剂,可引起肺血管舒张,用于治疗肺动脉高压。 | |||
T41251 |
Taprostene
|
||
Taprostene (CG-4203) 是一种合成的、化学稳定的前列环素 (PGI2) 类似物。Taprostene 对猫急性心肌缺血再灌注后内皮和心肌有保护作用。Taprostene 增强细胞保护作用,同时减少不必要的血液动力学影响。 | |||
T35943 |
15(S)-HpETE
|
||
15(S)-HpETE is a monohydroperoxy polyunsaturated fatty acid (PUFA) produced by the action of 15-lipoxygenase (15-LO) on arachidonic acid. It is either metabolized to 14,15-leukotriene A4 [1] or reduced to 15(S)-HETE by peroxidases.[2] [1] 15(S)-HpETE mediates a number of biological functions including the induction of c-fos and c-jun, and activation of AP-1. [3] 15(S)-HpETE inhibits prostacyclin synthesis in porcine aortic microsomes and bovine endothelial cells, and can cause the suicide inac... | |||
T36212 |
16(S)-Iloprost
|
||
Iloprost is a second generation structural analog of prostacyclin (PGI2) with about ten-fold greater potency than the first generation stable analogs, typified by carbaprostacyclin. Iloprost binds with equal affinity to the recombinant human IP and EP1 receptors with a Ki value of 11 nM. Most preparations of iloprost contain 16(S) and 16(R) stereoisomers. 16(S)-Iloprost potently inhibits platelet aggregation with an IC50 value of 3.5 nM. | |||
TMIH-0519 |
Selexipag Active Metabolite-d7
|
||
Selexipag Active Metabolite-d7 是 Selexipag Active Metabolite 的氘代化合物。Selexipag Active Metabolite 的 CAS 号为 475085-57-5。MRE269 是一种口服的长效前列环素受体激动剂前药,是 Selexipag 的活性代谢物,用于治疗肺动脉高压。 | |||
T37234 |
(±)14(15)-EpETE
|
||
EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators. Cytochrome P450 (CYP450) metabolism of polyunsaturated fatty acids, produces epoxides such as (±)14(15)-EpETrE which are prime candidates for the actual active mediator. However, the CYP450 metabolites of eicosapentaenoic acid and docosahexaenoi... | |||
T36552 |
CG 4305
|
||
Prostacyclin (PGI2) is a cyclooxygenase metabolite with antithrombotic properties found in vascular endothelial cells. The half-life is short both in vivo and in vitro, ranging from 30 seconds to a few minutes. CG 4305 is a stable carbacyclic analog of PGI2 that inhibits ADP-induced platelet aggregation 25% at a concentration of 50 nM. Doses of 10 mg/kg (oral) or 1 mg/kg (intraduodenal) have been shown to prevent rabbit carotid artery thrombosis. | |||
T70865 |
BMY-42393
|
||
BMY-42393 is orally active and selective platelet aggregation inhibitor. BMY-42393 is also a prostacyclin partial agonist that inhibited ADP, collagen and thrombin-induced platelet aggregation (IC50 range 0.3 - 2.0 microM). BMY-42393 stimulated platelet adenylate cyclase activity (EC50 = 25 nM). Platelets treated with BMY 42393 showed an elevation of cAMP levels and activation of cAMP-dependent protein kinase. BMY 42393 also inhibited thrombin-induced elevation of intracellular free calcium. B... | |||
T37238 |
(±)19(20)-EpDPA
|
||
EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators. Cytochrome P450 (CYP450) metabolism of polyunsaturated fatty acids produces epoxides such as (±)14(15)-EpETrE which are prime candidates for the actual active mediator. However, the CYP450 metabolites of eicosapentaenoic acid and docosahexaenoic... | |||
T37235 |
(±)16(17)-EpDPA
(±)16,17-EpDPE,(±)16,17 EDP,(±)16,17-epoxy Docosapentaenoic Acid,(±)16,17-epoxy DPA,(±)16(17)-EpDPA |
||
EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators.[1],[2]Cytochrome P450 (CYP450) metabolism of polyunsaturated fatty acids produces epoxides such as (±)14(15)-EET which are prime candidates for the actual active mediator.[3] However, the CYP450 metabolites of eicosapentaenoic acid and docosahex... | |||
T65598 | Cefminox sodium | ||
Cefminox (Sodium) is a new cephamycin antibiotic possessing a D-amino acid moiety derived from D-cysteine at the C-7B side chain. Cefminox is active against a wide range of bacteria, especially Gram-negative and anaerobic bacteria. Cefminox shows excellent in vivo efficacy (ED50) which is higher than would be expected from its in vitro activity (MIC). Moreover, cefminox possesses more potent activity in suppression of bacterial regrowth than other cephems[1]. Cefminox (Sodium) was the most activ... | |||
T35789 |
Palmitic acid-1-13C
|
||
Palmitic acid-13C is intended for use as an internal standard for the quantification of palmitic acid by GC- or LC-MS. Palmitic acid is a 16-carbon saturated fatty acid. It comprises approximately 25% of human total plasma lipids.1 It increases protein levels of COX-2 in RAW 264.7 cells when used at a concentration of 75 μM.2 Palmitic acid is involved in the acylation of proteins to anchor membrane-bound proteins to the lipid bilayer.2,3,4,5,6 |1. Santos, M.J., López-Jurado, M., Llopis, J., et a... | |||
T35791 |
Palmitic acid-13C
|
||
Palmitic acid-13C is intended for use as an internal standard for the quantification of palmitic acid by GC- or LC-MS. Palmitic acid-13C contains 13C at the C2 position and has been used in the study of free fatty acid incorporation into phospholipid fatty acids in soil microbes.1 Palmitic acid is a 16-carbon saturated fatty acid. It comprises approximately 25% of human total plasma lipids.2 It increases protein levels of COX-2 in RAW 264.7 cells when used at a concentration of 75 μM.3 Palmitic ... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TMA0536 |
2-Acetylbenzoic acid
|
Prostaglandin Receptor | GPCR/G Protein; Immunology/Inflammation |
2-Acetylbenzoic acid 在抑制血小板功能和血小板前列腺素 (PG) 合成方面比 2-丙酰氧基苯甲酸更有效,尽管这些药物在抑制前列环素 (PGI2) 合成方面的效力相当。 | |||
T3S2007 |
MRE-269
3-氧代-12-烯-28-乌苏酸,MRE 269,ACT-333679,MRE269 |
Prostaglandin Receptor | GPCR/G Protein; Immunology/Inflammation |
MRE-269 (ACT-333679) 是一种口服的长效前列环素受体激动剂前药,是 Selexipag 的活性代谢物,用于治疗肺动脉高压。 | |||
T73776 |
13-Hydroxyoctadecadienoic acid
|
||
13-hydroxyoctadecadienoic acid (13-HODE) 是 Linoleic acid 的一种内源性脂氧合酶代谢产物。13-hydroxyoctadecadienoic acid 通过增强磷脂中花生四烯酸 (AA) 的释放来刺激前列环素的产生。 |